Your browser doesn't support javascript.
loading
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
Mease, Philip J; Warren, Richard B; Nash, Peter; Grouin, Jean-Marie; Lyris, Nikos; Willems, Damon; Taieb, Vanessa; Eells, Jason; McInnes, Iain B.
Afiliación
  • Mease PJ; Swedish Medical Center/Providence St. Joseph Health and University of Washington, 601 Broadway, Seattle, WA, 98122, USA. pmease@phillipmease.com.
  • Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK.
  • Nash P; School of Medicine, Griffith University School of Medicine, Brisbane, QLD, Australia.
  • Grouin JM; University of Rouen, Rouen, France.
  • Lyris N; UCB Pharma, Slough, UK.
  • Willems D; UCB Pharma, Brussels, Belgium.
  • Taieb V; UCB Pharma, Colombes, France.
  • Eells J; UCB Pharma, Slough, UK.
  • McInnes IB; College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Rheumatol Ther ; 2024 Aug 09.
Article en En | MEDLINE | ID: mdl-39120849
ABSTRACT

INTRODUCTION:

The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR) was assessed at 52 weeks (Wk52) using matching-adjusted indirect comparisons (MAIC).

METHODS:

Relevant trials were systematically identified. For patients who were bDMARD naïve, individual patient data (IPD) from BE OPTIMAL (NCT03895203; N = 431) were matched with summary data from KEEPsAKE-1 (NCT03675308; N = 483). For patients who were TNFi-IR, IPD from BE COMPLETE (NCT03896581; N = 267) were matched with summary data from the TNFi-IR patient subgroup in KEEPsAKE-2 (NCT03671148; N = 106). To adjust for cross-trial differences, patients from the bimekizumab trials were re-weighted to match the baseline characteristics of patients in the risankizumab trials. Adjustment variables were selected based on expert consensus (n = 5) and adherence to established MAIC guidelines. Recalculated bimekizumab Wk52 outcomes for American College of Rheumatology (ACR) 20/50/70 response criteria and minimal disease activity (MDA) index (non-responder imputation) were compared with risankizumab outcomes via non-placebo-adjusted comparisons.

RESULTS:

In patients who were bDMARD naïve, bimekizumab had a significantly greater likelihood of response than risankizumab at Wk52 for ACR50 (odds ratio [95% confidence interval] 1.52 [1.11, 2.09]) and ACR70 (1.80 [1.29, 2.51]). In patients who were TNFi-IR, bimekizumab had a significantly greater likelihood of response than risankizumab at Wk52 for ACR20 (1.78 [1.08, 2.96]), ACR50 (3.05 [1.74, 5.32]), ACR70 (3.69 [1.82, 7.46]), and MDA (2.43 [1.37, 4.32]).

CONCLUSIONS:

Using MAIC, bimekizumab demonstrated a greater likelihood of efficacy in most ACR and MDA outcomes than risankizumab in patients with PsA who were bDMARD naïve and TNFi-IR at Wk52. TRIAL REGISTRATION NCT03895203, NCT03896581, NCT03675308, NCT03671148.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Rheumatol Ther Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Rheumatol Ther Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido